Logo

Cellumen, NCTR Collaborate on Liver Toxicity Testing

Jun 30, 2008
NEW YORK (GenomeWeb News) – Cellumen said today that it has entered into a research collaboration with the National Center for Toxicological Research, part of the US Food and Drug Administration, to test known liver toxicity drugs.
 
Cellumen will use its CellCiphr cell-based assay to create profiles of blinded samples of these compounds from failed and marketed drugs, and the NCTR will incorporate information about these drugs into a liver toxicity knowledge database.
 
The company said that its profiling technology can be used by drug companies to identify “compounds with high human toxic liabilities,” allowing drug companies to take actions or to measure the risk of certain compounds.
 
Cellumen also said it plans to use the profiling and safety data from the collaboration to continue to develop the CellCiphr database, cell panels, and informatics tools.

Breaking News
The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.